MIF在NSCLC患者血清中的表达及DP方案化疗对其水平的影响  

Expression of macrophage migration inhibitory factor(MIF) in NSCLC and the effects of DP program chemotherapy on them

作　　者：逯峰[1] 马德晶[2] 翟乃亮[1] 夏永富[1] 

机构地区：[1]滨州医学院附属医院呼吸内科,滨州256003 [2]滨州医学院附属医院放射科

出　　处：《滨州医学院学报》2015年第6期430-431,435,共3页Journal of Binzhou Medical University

基　　金：滨州医学院科技计划项目(BY2011KJ042)

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者血清中巨噬细胞移动抑制因子(MIF)的表达水平及DP方案(多西他赛联合顺铂)化疗对MIF水平的影响。方法选取40例NSCLC患者对其进行临床分期,给予DP方案化疗,分别测定首次化疗前及化疗4次后血清MIF水平;对照组选取8名健康受试者测定血清MIF水平。结果Ⅰ、Ⅱ期NSCLC患者血清中MIF水平较正常组对比无显著差异(P>0.05),Ⅲ、Ⅳ期NSCLC患者血清MIF水平较对照组升高(P<0.01);通过铂类联合化疗Ⅲ、Ⅳ期NSCLC患者血清MIF水平较前下降(P<0.01)。结论Ⅲ、Ⅳ期NSCLC患者血清MIF明显高于正常水平,经4次铂类联合化疗后MIF水平有所下降。Objective To observe the serum levels of MIF in non-small cell lung cancer（NSCLC）patients,and explore the effects of DP program chemotherapy on the MIF level.Methods Forty NSCLC patients were divided into 3groups by clinical stage,all the patients received DP program chemotherapy,and serum levels of MIF were detected at the point of before the first chemotherapy and after the fourth chemotherapy.Eight healthy volunteer were chosen into the control group,and serum was also saved for detecting the levels of MIF.Results There was no significant difference between the Ⅰ/Ⅱ clinical stage NSCLC and control group in the serum levels of MIF.The serum levels of MIF in Ⅲ and Ⅳ clinical stage NSCLC patients were significantly higher than those of the control group（P〈0.01）.The MIF levels of them significantly decreased after the treatment with platinum-based chemotherapy（P〈0.01）.Conclusion Serum levels of MIF increased significantly in NSCLC patients at Ⅲ/Ⅳ clinical stage,the levels decreased significantly after the treatment with platinum-based chemotherapy.

关 键 词：巨噬细胞移动抑制因子 非小细胞肺癌 顺铂 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]